Single-ascending Dose Study of Kylo-12 in Healthy Subjects

Summary

This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-12 will be evaluated in approximately 50 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.

Timeline

Start

2025-03-12

Primary completion

2025-12-19

Completion

2026-08-30

Drugs

Indications